Approximately 23% of AML patients possess an activating internal tandem duplication (ITD) mutation in the juxtamembrane (JM) domain/kinase domain (TK) of FLT3 (FLT3-ITD) and 7% patients possess a point mutation (D835) in the kinase domain (KD)4. The gene discussed is FLT3; the disease is acute myeloid leukemia.